What are the versions of Gifapisheng tablets? How much do they cost?

Gemfapixin tablets are the world's first P2X3 receptor antagonist, providing innovative treatment options for patients with refractory chronic cough. This drug, jointly developed by Merck and Japan's Kyorin Pharmaceuticals, has multiple versions in different countries and regions. This article will introduce in detail the main versions of Gefavixin Tablets, the price differences of each version, and the launch progress in the Chinese market to help patients fully understand the accessibility of this innovative drug.

What are the versions of Gifapisheng tablets?

There are currently three official versions of Gifapisheng tablets around the world, which are developed for different markets and have differences in packaging and specifications.

Japan Xinglin version

The original version produced by Japan Xinglin Pharmaceutical, the trade name is Lifnua. The specification is 45mg*100 tablets/box, and it is designed with pink round film-coated tablets. The packaging is printed with Japanese instructions and the Xinglin Pharmaceutical logo. This version is the earliest original version approved for marketing.

US Merck version

The version sold in the US market is produced by Merck under the trade name Lyfnua. The specifications are also 45mg*100 tablets/box.

The core ingredients and curative effects of each version of Gefavixin Tablets are the same. The main differences lie in packaging design and regional adaptability.

How much do the different versions of Gyfapisheng tablets cost?

The prices of Gyfapisin tablets vary significantly depending on regions, medical insurance policies and purchase channels.

Price of Japanese Apricot Forest Edition

The price of Japanese Apricot Forest Edition is approximately US$223 per box. Based on a standard dose twice daily, the monthly treatment cost is approximately US$134.

US Merck version price

The price in the US market is higher, and patients’ out-of-pocket costs are lower after commercial insurance reimburses them, while uninsured patients have to bear the full cost.

The price of Gefavixin tablets reflects its innovative drug attributes, and patients can choose the most economical way to obtain it according to local medical insurance policies.

The launch and medical insurance situation of Gyfapisin tablets in China

The entry of Gyfapisin tablets into the Chinese market is in progress and has not yet been officially launched.

Registration and Approval Progress

As of August 2025, Gefapixen Tablets has not submitted a marketing application to the China State Food and Drug Administration, and it is expected to start the Chinese registration process after completing the main market layout in Europe and the United States.

Expected inclusion in medical insurance

As an innovative drug that is urgently needed in clinical practice, Gemfapisin Tablets is expected to be accelerated to the market through the priority review channel. If approved, it may first enter the national medical insurance negotiation directory, but the reimbursement rate depends on the outcome of the negotiation.

Patient acquisition channels

At this stage, Chinese patients can obtain it in three ways: purchasing prescriptions from overseas legal medical institutions; domestic medical service institutions; and participating in domestic clinical trials. Pay attention to the authenticity of the medicine and transportation and storage conditions.

The launch of Gemfapixin tablets in the Chinese market will greatly improve the accessibility of treatment for patients with refractory chronic cough, which is worth looking forward to.